AFMD Affimed NV: Earnings per share for the last twelve months

Affimed (AFMD) current cash reserves support the development of oncology programs, leading to planned capital expenditure. The net income per share over the last 12 months illustrates this trend, with the figure recorded at -5.06. Efficiency is based on the ROCK platform for NK-cell activation against lymphomas, while environmental responsibility is reflected in the optimization of water consumption and filtration within laboratories.

Investors must evaluate the actual capital generation efficiency of Affimed (AFMD) to determine the asset's fundamental value. This indicator measures the net income distributed per common share over a rolling year. By analyzing the earnings per share (EPS) over the last 12 months, one can track the dynamics of business value creation. For the biotechnology sector, this result depends directly on the costs of specialized drug transportation. The security of logistics chains critically impacts the company's final profitability.